Every S-3 that Solid Biosciences Inc. (SLDB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow SLDB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLDB filings page.
Solid Biosciences Inc. filed a Form S-3 automatic shelf registration statement that allows it to offer, from time to time after effectiveness, a mix of debt securities, common stock, preferred stock, depositary shares, warrants and units. Specific terms and amounts for each issuance will be set in later prospectus supplements.
The company, a gene therapy-focused life sciences business with programs including SGT-003 for Duchenne muscular dystrophy and other rare cardiac and neuromuscular conditions, states that net proceeds from any offerings are expected to be used for general corporate purposes, including R&D, clinical development, strategic transactions, debt repayment, working capital and capital expenditures.
The filing also details the general terms of potential senior and subordinated debt, capital stock (including “blank check” preferred stock), depositary shares, warrants, and units, as well as registration rights held by certain investors and anti-takeover provisions under Delaware law and the company’s governing documents.
Solid Biosciences Inc. is registering up to 42,780,739 shares of its common stock for resale, to be sold from time to time by the selling stockholders named in the prospectus. The registration covers 27,807,482 shares issuable upon exercise of pre-funded warrants issued in the March 2026 private placement.
The prospectus states the company will not receive any proceeds from sales by the selling stockholders. The March 2026 Private Placement closed on March 9, 2026, when the company issued 14,973,257 shares and pre-funded warrants and received gross proceeds of $240.0 million before fees and expenses. Shares outstanding were 98,391,314 as of March 10, 2026.
Solid Biosciences Inc. files a registration statement to register the resale of 1,316,899 shares of its common stock on behalf of selling stockholder FA212 LLC. The shares were issued in private placements under an Asset Purchase Agreement, and the company will receive no proceeds from resales.
The registration covers resale by FA212 LLC of shares issued on January 15, 2026 following dosing in a Phase 1b trial of SGT-212. The prospectus states the selling stockholder may sell shares in public or private transactions, and Solid will bear registration expenses while FA212 LLC will pay sales-related fees.